Viking Therapeutics VKTX Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Viking Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Viking Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viking Therapeutics's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viking Therapeutics's retained earnings?
- Viking Therapeutics (VKTX) reported retained earnings of -$1.01B in Q1 2026.
- How has Viking Therapeutics's retained earnings changed year-over-year?
- Viking Therapeutics's retained earnings decreased by 88.5% year-over-year, from -$533.54M to -$1.01B.
- What is the long-term trend for Viking Therapeutics's retained earnings?
- Over 5 years (2020 to 2025), Viking Therapeutics's retained earnings has grown at a 38.2% compound annual growth rate (CAGR), from -$168.19M to -$847.55M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.